Tag: change

LITTLE ROCK, Ark., June 01, 2026 (GLOBE NEWSWIRE) -- Uniti Group Inc. (the “Company,” “Uniti,” or “we”) (Nasdaq: UNIT) today announced that Kinetic ABS Issuer LLC, a limited-purpose, bankruptcy remote subsidiary of Uniti (the “Issuer”), has commenced an offering of $1,140,710,000 aggregate principal amount of secured fiber network revenue term notes (the “Notes”), the issuance and sale of which are subject to market conditions and other factors. The Notes are expected to have an anticipated repayment date in June 2033. The Notes are expected to be secured by certain residential fiber network assets and related customer agreements in the States of Texas, Arkansas, Kentucky, Ohio, Georgia, Iowa, Alabama, Florida, North Carolina and Oklahoma. Each of the Issuer and its direct parent entity and subsidiaries are designated as “unrestricted subsidiaries” under Uniti’s credit agreement and the indentures governing its outstanding senior notes.

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ^®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada¹ and complements the adolescent label extension received in Europe in April 2025².

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Reddit (RDDT) To Contact Him Directly To Discuss Their Options

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

Plumbing contractors in 2025 across the United States face rising costs, tighter lending standards, and limited access to traditional credit. ROK Financial’s expansion of no credit check business loan programs responds to growing demand for flexible financing, offering contractors new pathways to secure working capital and sustain growth despite credit challenges.

Demand for the best HVAC business loans for bad credit in 2025 is climbing nationwide as ROK Financial expands no credit check financing programs, offering heating and cooling contractors faster access to working capital amid rising costs and tighter credit standards.

Contractors facing credit challenges in 2025 are fueling record demand for alternative financing, as ROK Financial expands business loan programs designed to keep projects funded and crews working nationwide.

The best no credit check business financing options in 2025 are gaining momentum as small business owners face tighter traditional lending standards and rising uncertainty in the economy. ROK Financial is meeting this demand with flexible loan programs, instant pre-approvals, and expanded access to capital for entrepreneurs across industries. By offering a range of solutions — from working capital and SBA loans to equipment and real estate financing — the company reflects a larger movement toward credit-independent funding that aligns with modern business needs.

Washington, DC, Aug. 15, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/08/15/week-30-of-america-in-the-trump-administration/?_thumbnail_id=32940

Learn how Honest Loans connects US borrowers to quick $1,000 online loans with a simple application process and flexible options.

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.